---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-022397"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:25:27.330501+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Esperion Q1 total revenue $65.0M (-53% Y/Y); US product revenue up 41% to $34.9M

## Summary
- Net loss $40.5M ($0.21 EPS loss) vs net income $61.0M ($0.36 EPS) in Q1 2024 due to prior-year milestone.
- Collaboration revenue $30.1M (-73% Y/Y) on $100M milestone in Q1 2024; ex-milestone +97%.
- Commercial: surpassed 1M US prescriptions; reimbursement team expanded from 5 to 15 specialists.
- Pipeline: unveiled PSC candidate ESP-1336 (>$1B market); triple-combination products on track for 2027.
- 2025 op-ex guidance $215-235M (incl. ~$15M stock comp); cash $114.6M at quarter end.

## SEC filing metadata
- accession: 0001628280-25-022397
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828025022397/0001628280-25-022397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828025022397/espr-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-022397
- JSON: https://secwatch.observer/filing/0001628280-25-022397.json
- Plain text: https://secwatch.observer/filing/0001628280-25-022397.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.